Despite a shifting landscape in the U.S., Canada and Latin America for the  pharmaceutical industry and an ever more challenging business environment,  we are continuing to grow a robust business in the Americas region and  aggressively pursue opportunities that further reinforce our strength. This has  been accomplished by ensuring best-in-class launches of our innovative  therapies, including XTANDI and Myrbetriq, that serve the unmet needs of  patients. In addition, we continue to ensure we maintain our leadership   positions throughout our portfolio. To accomplish this, we ensure that we prioritize investments appropriately,  streamline our operations, improve our cost structure and focus on growth  opportunities that contribute to the success of the organization. Finally, we  continue to attract, develop and retain top talent in the industry to ensure  we are well positioned for the future. We will continue to focus on the needs  of patients, and ensure they are at the center of our priorities now and in  the future. Sales of Major Products Review of Operations Masao Yoshida President and CEO, Americas Operations (US$ million)  VESIcare   Myrbetriq  Tarceva   XTANDI 1,000 750 500 250 0 2012.3 2013.3 2014.3 2015.3 (Forecast) J-GAAP IFRS Sales/Revenues of Mainstay Products Annual Report 2014 _  Astellas Pharma Inc.  47 (US$ million) 2013.3 J-GAAP 2014.3 2015.3 (Forecast) IFRS J-GAAP IFRS Sales in the Americas 2,512 $_{⬆}$ 2,878 2,863 $_{⬆}$ 2,892 Immunosuppressant Prograf and ASTAGRAF XL 379 ⬇ 296 296 ⬇ 274 Pharmacologic stress agent Scan (Adenoscan and Lexiscan) 639 ⬇ 617 617 ⬇ 533 Lexiscan 572 $_{⬆}$ 585 585 Antifungal agent AmBisome 76 $_{⬆}$ 80 80 ➡ 80 Treatment for atopic dermatitis Protopic 95 $_{⬆}$ 116 116 ⬇ 84 OAB treatment VESIcare 563 $_{⬆}$ 580 580 ⬇ 482 OAB treatment Myrbetriq (Launched in October 2012) 20 $_{⬆}$ 145 145 $_{⬆}$ 259 Candin-type antifungal agent MYCAMINE 114 $_{⬆}$ 117 117 ⬇ 109 Lung and pancreatic cancer treatment Tarceva 440 $_{⬆}$ 446 446 US 284 $_{⬆}$ 288 288 Outside of the US 156 $_{⬆}$ 158 158 Prostate cancer treatment XTANDI (Launched in September 2012) 147 $_{⬆}$ 450 450 $_{⬆}$ 560* * Forecast for the U.S. only